Castle Biosciences CEO Sells $106,598 in Shares CEO Maetzold sold $106,598 of Castle Biosciences stock on Mar 30, 2026 (Investing.com); the modest sale merits scrutiny of Form 4 details and company catalysts.

Castle Biosciences CEO Sells $106,598 in Shares: CEO Maetzold sold $106,598 of Castle Biosciences stock on Mar 30, 2026 (Investing.com); the modest sale merits scrutiny of Form 4 details and company catalysts. 👈 Read full analysis #CastleBiosciences #CSTL #Investing #StockMarket #CEO

Castle Biosciences Files Form 144 for Insider Sale Castle Biosciences filed Form 144 on Mar 26, 2026, triggering a 90-day sale window; Rule 144 applies when sales exceed 5,000 shares or $50,000 (SEC).

Castle Biosciences Files Form 144 for Insider Sale: Castle Biosciences filed Form 144 on Mar 26, 2026, triggering a 90-day sale window; Rule 144 applies when sales exceed 5,000 shares or $50,000 (SEC). 👈 Read full analysis #CastleBiosciences #InsiderTrading #Form144 #SEC #StockMarket

Castle Biosciences Expands into Atopic Dermatitis Diagnostics with New SciBase Partnership Castle Biosciences (NASDAQ: CSTL) announced a new collaboration and license agreement with SciBase to co-develop diagnostic tools for dermatologic diseases, sta

#CSTL is expanding into atopic dermatitis diagnostics through a new partnership with SciBase. The goal: develop a test to predict AD flares before symptoms appear. Aimed at a U.S. patient base of up to 24M.
#CastleBiosciences
prismmarketview.com/castle-biosc...